Audio Library

Prevention of stroke in patients with atrial fibrillation and comorbidities

Anticoagulation in high risk patients with atrial fibrillation – Episode 1

In this episode, Dr Yassir Javaid gives us his advice on getting to know your patients with atrial fibrillation and diabetes , Professor Craig Coleman explains the results of the CALLIPER study and Dr Manesh Patel and Dr Christian Ruff look at the issues surrounding stroke prevention in an older patient with renal impairment and tell us how COVID-19 is affecting the treatment of patients with cardiovascular disease.

PP-XAR-ALL-1800-1

PP-M_RIV-ALL-0113-1

For more information on the number of strokes that can be prevented click here https://eiuperspectives.economist.com/healthcare/policy-approaches-stroke-prevention/white-paper/preventing-stroke-uneven-progress
Details on the number of patients of atrial fibrillation and comorbid diabetes can be found on our page on Thrombosis Adviser www.thrombosisadviser.com/diabetes
Data showing how diabetes doubles the rate of renal decline over 2 years are available in this publication pubmed.ncbi.nlm.nih.gov/27073197/
Full results of the CALLIPER study are presented here https://academic.oup.com/eurheartj/article-abstract/40/Supplement_1/ehz745.1122/5596296?redirectedFrom=fulltext
The 2019 American Heart Association/American College of Cardiology/Heart Rhythm Society Focused Update of the Guideline for the Management of Patients With Atrial Fibrillation is available here https://www.ncbi.nlm.nih.gov/pubmed/30703431
The European Society of Cardiology Guidelines for the Management of Atrial Fibrillation can be read here pubmed.ncbi.nlm.nih.gov/16531986/
For anticoagulant dosing information see the European labels for apixaban (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf), dabigatran (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf), edoxaban (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002629/WC500189045.pdf), rivaroxaban (https://www.ema.europa.eu/documents/product-information/xarelto-epar-product-information_en.pdf) and warfarin (www.medicines.org.uk/emc/product/3064/smpc)

Anticoagulation in high risk patients with atrial fibrillation - Episode 2

In this episode, Professor Peter Rossing talks about the links between atrial fibrillation and diabetes, Professor Craig Coleman takes us through the RIVAL study and Dr Manesh Patel and Dr Christian Ruff discuss the management of an obese patient with atrial fibrillation and diabetes.

PP-XAR-ALL-1885-1

PP-M_RIV-ALL-0111-1

Details on the affect that diabetes has on stroke risk in patients with atrial fibrillation can be found on our page on Thrombosis Adviser (www.thrombosisadviser.com/diabetes).
Data showing how diabetes doubles the rate of renal decline over 2 years are available in this publication (www.ncbi.nlm.nih.gov/pubmed/27073197)
Full results of the RIVAL study are presented here (pubmed.ncbi.nlm.nih.gov/31392894/)
Subanalyses of the ROCKET AF trial that look at the effect of rivaroxaban on atherosclerotic events in patients with atrial fibrillation can be seen here (pubmed.ncbi.nlm.nih.gov/24132190/) (for coronary events) and here (pubmed.ncbi.nlm.nih.gov/24302273/) for limb events
The MarketScan analysis looking at major cardiovascular or limb events in patients with atrial fibrillation and diabetes are published here: (https://dom-pubs.onlinelibrary.wiley.com/doi/abs/10.1111/dom.13787)
The 2019 American Heart Association/American College of Cardiology/Heart Rhythm Society Focused Update of the Guideline for the Management of Patients With Atrial Fibrillation is available here (www.ncbi.nlm.nih.gov/pubmed/30703431)
More information on COMPASS and VOYAGER PAD can be found on VascularAdviser.com (www.thrombosisadviser.com/en/vascular-protection/)
The European Society of Cardiology Guidelines for the Management of Atrial Fibrillation can be read here (www.ncbi.nlm.nih.gov/pubmed/16531986)
For anticoagulant dosing information see the European labels for apixaban (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf), dabigatran (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf), edoxaban (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002629/WC500189045.pdf), rivaroxaban (https://www.ema.europa.eu/documents/product-information/xarelto-epar-product-information_en.pdf) and warfarin (www.medicines.org.uk/emc/product/3064/smpc)

Anticoagulation in high risk patients with atrial fibrillation – Episode 3

In this episode, Dr Rónán Collins talks about the links between atrial fibrillation and renal impairment, Dr Hendrik Bonnemeier takes us through the RELOADED study and Dr Manesh Patel and Dr Christian Ruff discuss the management of an patient with atrial fibrillation, diabetes and renal impairment.

PP-XAR-ALL-1963-1

PP-M_RIV-ALL-0127-1

The 2018 EHRA Practical Guide on the use of NOACs in patients with atrial fibrillation can be found here https://academic.oup.com/eurheartj/article/39/16/1330/4942493
The meta-analysis of the phase III trials of NOACs by Ruff et al. is available here pubmed.ncbi.nlm.nih.gov/24315724/
Recent presentations of data from RELOADED can be found here (https://esc365.escardio.org/vgn-ext-templating/Congress/ESC-CONGRESS-2019/Poster-Session-5-Atrial-fibrillation-and-oral-anticoagulation-6/199357-comparative-safety-of-factor-xa-inhibitors-vs-phenprocoumon-in-patients-with-non-valvular-atrial-fibrillation-and-renal-disease-insights-from-the-reloaded-study#slide) and here (https://esc365.escardio.org/Congress/ESC-CONGRESS-2019/Poster-Session-5-Atrial-fibrillation-and-oral-anticoagulation-1/199283-renal-function-worsening-in-factor-xa-inhibitors-vs-phenprocoumon-in-patients-with-non-valvular-atrial-fibrillation-and-renal-disease-insights-from-the-reloaded-study) and RELOAD is published here (www.ncbi.nlm.nih.gov/pmc/articles/PMC6510975/).
Thrombosis Adviser’s coverage of ESC 2019 is here (www.thrombosisadviser.com/esc-spaf/)
The 2019 American Heart Association/American College of Cardiology/Heart Rhythm Society Focused Update of the Guideline for the Management of Patients With Atrial Fibrillation is available here www.ncbi.nlm.nih.gov/pubmed/3070343
The European Society of Cardiology Guidelines for the Management of Atrial Fibrillation can be read here www.ncbi.nlm.nih.gov/pubmed/16531986
For anticoagulant dosing information see the European labels for apixaban (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf), dabigatran (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf), edoxaban (http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002629/WC500189045.pdf), rivaroxaban (https://www.ema.europa.eu/documents/product-information/xarelto-epar-product-information_en.pdf) and warfarin (www.medicines.org.uk/emc/product/3064/smpc)

Interview with Dr Yassir Javaid

Dr Yassir Javaid talks to Thrombosis Adviser about patients with atrial fibrillation and diabetes.

PP-XAR-ALL-1881-1

PP-M_RIV-ALL-0114-1